DelMar Pharmaceuticals, Inc. announced that Mr. Saiid Zarrabian has joined the company's Board of Directors and Dr. Erich Mohr has been elected to serve as its Chairman. This Board strengthening initiative seeks to establish a more robust and independent Board, and to enable Jeffery Bacha, who has been both the Company's CEO and chairman since inception in 2010, to focus on his growing operational role as CEO. Saiid Zarrabian comes to DelMar with over 30 years of senior executive or board member experience for multiple public and private companies, culminating in the creation of more than three billion dollars of shareholder value. Mr. Zarrabian is currently serving as an advisor to Redline Capital Partners, S.A. Dr. Erich Mohr, Ph.D., R. Psych., has served as a director of DelMar since March 31, 2015 and has nearly two decades of biotechnology experience in executive leadership roles as co-founder, chief scientific officer, chief executive officer and board member.